Advertisement

General Aspects of Cancer Chemotherapy in the Aged

  • Ronald A. Fleming
  • Robert L. Capizzi
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 330)

Abstract

Age is one of the most important prognostic factors affecting outcome in the treatment of patients with neoplastic diseases. The negative impact of age is almost uniformly encountered with any solid tumor or hematologic malignancy. Detailed analysis of the negative implications of age on therapeutic outcome uncover tumorrelated factors, host-related factors and some degree of the interaction between tumor and host-related factors. For example, it is generally accepted that histologic or cytologie subtype of Hodgkin’s Disease or the acute leukemias have an important effect on outcome. The general observation is that the prognosis for Hodgkin’s Disease is worse on older i.e. > 60 years of age compared to younger patients i.e. in the 20–30 year age group. However, it is not the diagnosis of Hodgkin’s Disease per se that has a poorer prognosis in elderly patients but rather the impact of a more aggressive variant of Hodgkin’s Disease (lymphocyte depleted) which has a higher frequency of occurrence in elderly patients compared to younger patients. Likewise, the frequency and duration of response as well as curability of ALL1 in elderly patients is much lower than that possible in children. Reasons for this lesser effect include the fact that elderly patients with ALL have not only a higher frequency of biphenotypic ALL but also a higher frequency of Philadelphia chromosome positive ALL, both of which have negative prognostic implications in any age group. Older patients with AML1 more commonly have a history of antecedent myelodysplasias or secondary leukemias, historical features that have a negative prognostic impact in any age group.

Keywords

Anticancer Drug Anticancer Agent Dose Intensity Antineoplastic Agent Renal Plasma Flow 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Allen, C., Cox, E.B., Manton, K.G., Cohen, H.J. Breast cancer in the elderly. Current patterns of care. J. Amer. Geriatr. Soc. 34:637–642 (1986).Google Scholar
  2. Bagley, C.M. Jr., Bostick, F.W. and DeVita, V.T. Jr. Clinical pharmacology of cyclosphosphamide. Cancer Res. 33:226–233 (1973).PubMedGoogle Scholar
  3. Begg, C.B. and Carbone, P.P. Clinical trials and drug toxicity in the elderly. The experience of the Eastern Cooperative Oncology Group. Cancer 52:1986–1992 (1983).PubMedCrossRefGoogle Scholar
  4. Bennett, C.L., Sinkule, J.A., Schilsky, R.L., Senekjian, E., Choi, K.E. Phase I clinical and pharmacological study of seventy-two hour continuous infusion of etoposide in patients with advanced cancer. Cancer Res. 47:1952–1956 (1987).PubMedGoogle Scholar
  5. Bonnadonna, G. and Valagussa, P. Dose-response effect of adjuvant chemotherapy in breast cancer. New Engl. J. Med. 304:10–15 (1981).CrossRefGoogle Scholar
  6. Bruce, W. B., Meeker, B. E., Valeriote, F. A. Comparison of the sensitivity of normal hematopoietic and transplanted lymphoma colony forming cells to chemotherapeutic agents administered in vivo. J. Natl. Cancer Inst. 36:233–247 (1966).Google Scholar
  7. Carde, P., MacKintosh, F. R. and Rosenberg, S. A. A dose and time response analysis of the treatment of Hodgkin’s disease with MOPP chemotherapy. J. Clin. Oncol. 1:146–153 (1983).PubMedGoogle Scholar
  8. Cohen, H. J., Silberman, H.R., Forman, R., Bartolucci, A. and Liu, C. Effects of age on responses to treatment and survival of patients with multiple myeloma. J. Amer. Geriatr. Soc. 31:272 (1983).Google Scholar
  9. Cohen, H.J. and Bartolucci, A. Age and the treatment of multiple myeloma. Southeastern Cancer Study Group experience. Amer. J. Med. 79:316–324 (1985).PubMedCrossRefGoogle Scholar
  10. Cohen, M.H., Creaven, P.J., Fossiek, B.E. Jr., et al. Intensive chemotherapy of small cell bronchogenic carcinoma. Cancer Treat Rep. 61:349–354 (1977).PubMedGoogle Scholar
  11. Cusack, B., Kelly, J., O’Malley, K. et al. Digoxin in the elderly: Pharmacokinetic consequences in old age. Clin. Pharmacol Then. 25:772–776 (1979).Google Scholar
  12. Davies, D.F., Shock, N.W. Age changes in glomerular filtration rate, effective renal plasma flow, and tubular excretory capacity in adult males. J. Clin. Invest. 29:496–507 (1950).PubMedCrossRefGoogle Scholar
  13. DeVita, V. T. Dose-response is alive and well. J. Clin. Oncol. 4:1157–1159 (1986).PubMedGoogle Scholar
  14. Divoll, M. and Greenblatt, D. J. Effect of age and sex on lorazepam protein binding. J. Pharmacol. 34:122–123 (1982).CrossRefGoogle Scholar
  15. Divoll, M., Greenblatt, D. J., Ochs, H. R., Shader, R. I. Absolute bioavailability of oral and intramuscular diazepam: effects of age and sex. Anesth. Analg. 62:1–8 (1983).PubMedCrossRefGoogle Scholar
  16. Egorin, M. J., Van Echo, D.A., Olman, E. A., Whitacre, M. Y., Forrest, A., and Aisner, J. Prospective validation of a pharmacologically based dosing scheme for the cis-diammine dichloroplatimun(II) analogue diamminecyclobutane dicarboxylatoplatinum. Cancer Res. 45:6502 (1985).PubMedGoogle Scholar
  17. Egorin, M. J., Van Echo, D. A., and Whitacre, M. Y. Human pharmacokinetics, excretion, and metabolism of the anthracycline menogaril (7-0MEN, NSC 269148) and their correlation with clinical toxicities. Cancer Res. 46:1513–1520 (1986).PubMedGoogle Scholar
  18. Evans, M. A., Triggs, E. J., Cheung, M., Broe, G. A., Creasey, H. Gastric emptying rate in the elderly: implications for drug therapy. J. Am. Geriatr. Soc. 29:201–205 (1981).PubMedGoogle Scholar
  19. Evans, W. E., Crom, W. R., Abromowitch, M., Dodge, R., Look A. T., Bowman, W.P., George, S. L. Clinical pharmacodynamics of high-dose methotrxate in acute lymphocytic leukemia. Identification of a relation between concentration and effect. New Engl. J. Med. 314:471–477 (1986).PubMedCrossRefGoogle Scholar
  20. Evans, W. E. and Relling, M. V. Clinical pharmacokinetics-pharmacodynamics of anticancer drugs. Clin Pharmacokin. 16:327–336 (1989).CrossRefGoogle Scholar
  21. Forrest, A., Conley, B.A., Egorin, M.J., Zuhowski, E., Jasman, N.M., Van Echo, D.A. Adaptive control of hexamethylene bisacetamide (HMBA) pharmacodynamics [Abstract]. Proc. Am. Soc. Clin. Oncol. 7:61 (1988).Google Scholar
  22. Gelman, R. S., Taylor, S. G. Cyclophosphamide, methotrexate and 5-fluorouracil chemotherapy in women more than 65 years old with advanced breast cancer: The elimination of age trends in toxicity by using doses based on Creatinine clearance. J. Clin. Oncol. 2:1404–1413 (1984).PubMedGoogle Scholar
  23. Greenblatt, D. J. Reduced serum albumin concentrations in the elderly: a report from the Boston Collaborative Drug Surveillance Program. J. Am. Geriatr. Soc. 27:20–22 (1979).PubMedGoogle Scholar
  24. Greenblatt, D. J, Allen, M.D., Harmatz, J. S., Shader, R. I. Diazepam disposition determinants. Clin. Pharmacol. Ther. 27; 301–312 (1980).PubMedCrossRefGoogle Scholar
  25. Greenfield, S., Blanco, D. M., Elashoff, R. M., Ganz, P. A. Patterns of care related to age of breast cancer patients. J. Am. Med. Assoc. 257:2110–2166 (1987).CrossRefGoogle Scholar
  26. Griswold, D. P., Laster, W. R., Snow, M. Y., Schabel, F. M., Jr. and Skipper, H. E. Experimental evaluation of potential anticancer agents. Cancer Res. 21(suppl 23):271–519 (1963).Google Scholar
  27. Humphrey, R.L. and Kvols, L.K. The influence of renal insufficiency on cyclophosphamide-induced hematopoietic depression and recovery. Proc. Am. Assoc. Cancer Res. 15:84 (1974).Google Scholar
  28. Hyrniuk, W. and Bush, H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J. Clin. Oncol. 2:1281–1288 (1984).Google Scholar
  29. Hyrniuk, W. and Levine, M. N. Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J. Clin. Oncol. 4:1162–1170 (1986).Google Scholar
  30. Hryniuk, W. M. Average dose intensity and the impact on design of clinical trials. Semin. Oncol. 14:65–74 (1987).PubMedGoogle Scholar
  31. Hryniuk, W. M. More is better. J. Clin. Oncol. 6:1365–1367 (1988).PubMedGoogle Scholar
  32. Kramer, P.A., Chapron, D.J., Benson, Mercik, S.A. Tetracycline absorption in elderly patients with achlorhydria. Clin. Pharmacol. Ther. 23:467–472 (1978).PubMedGoogle Scholar
  33. Liddell, D. E., Williams, F. M., Briant, R. H. Phenazone (antipyrine) metabolism and distribution in young and elderly adults. Clin. Exp. Pharmacol. Physiol. 2:481–487 (1975).PubMedCrossRefGoogle Scholar
  34. Miller, J. H., McDonald, R. K., Schock, N. W. Age changes in the maximal rate of tubular reabsorption of glucose. J. Gerontol. 7:196–200 (1952).PubMedCrossRefGoogle Scholar
  35. Moore, J. G., Tweedy, E. J., Christian, P. E., Datz F.L. Effect of age on gastric emptying of liquid-solid meals in man. Digestive Dis. Sci. 28:340–344 (1983).CrossRefGoogle Scholar
  36. Mor, V., Masterson-Allen, S., Goldberg, R. J., Cummings, F. J., Glicksman, A. S., Fretwell, M. D. Relationship between age at diagnosis and treatments received by cancer patients. J. Am. Geriatr. Soc. 33:585–589 (1985).PubMedGoogle Scholar
  37. Mouridsen, H. T. and Jacobsen, E. Pharmacokinetics of cyclophosphamide in renal failure. Acta. Pharmacol. Toxicol. 36:409–414 (1975).CrossRefGoogle Scholar
  38. Ozols, R. F. Cisplatin dose intensity. Semin. Oncol. 16(suppl 6):22–30 (1989).PubMedGoogle Scholar
  39. Patterson, M., Heazelwood, R., Smithurst, B., Eadie, M.J. Plasma protein binding of Phenytoin in the aged: in vivo studies. Br. J. Clin. Pharmacol. 13:423–425 (1982).PubMedCrossRefGoogle Scholar
  40. Peterson, B.A., Pajak, T.F., Cooper, M.R., Nissen, N.I., Glidewell, O.J., Holland, J.F., Bloomfield, C.D., Gottlieb, A.J. Effect of age on therapeutic response and survival in advanced Hodgkin’s disease. Cancer Treat Rep. 66:889–898 (1982).PubMedGoogle Scholar
  41. Pinkel, D., Hernandez, K., Borella, L., Holton, C., Aur, R., Samoy, G., Pratt, C. Drug dosage and remission duration in childhood lymphocytic leukemia. Cancer 27:247–256 (1971).PubMedCrossRefGoogle Scholar
  42. Ratain, M.J., Schilsky, R.L., Choi, K.E., Guarnieri, C., Grimmer, D., Vogelzang, N.J., Sinckjian, E., Liebner, M.A. Adaptive control of etoposide administration: Impact of interpatient pharmacodynamic variability. Clin. Pharmacol. Ther. 45:226–233 (1989).PubMedCrossRefGoogle Scholar
  43. Reidenberg, M. M. Drug therapy in the elderly: the problem from the point of view of a clinical pharmacologist. Clin. Pharmacol Ther. 42:677–680 (1987).PubMedCrossRefGoogle Scholar
  44. Rodman, J. H., Abromowitch, M., Sinkule, J. A., Hayes, F. A., Rivera, G. K., and Evans, W. E. Clinical pharmacodynamics of continuous infusion teniposide: Systemic exposure as a determinant of response in a phase I trial. J. Clin. Oncol. 5:1007–1014 (1987).PubMedGoogle Scholar
  45. Samet, J., Hunt, W. C., Key, C., Humble, C. G., Goodwin, J. S. Choice of cancer therapy varies with age of patient. J. Am. Med. Assoc. 255:3385–3390 (1986).CrossRefGoogle Scholar
  46. Schabel, F. M., Griswold, D. P., Corbett, T. H., Laster, W. R., Jr. Increasing the therapeutic response rates to anticancer drugs by applying the basic principles of pharmacology. Cancer 54:1160–1167 (1984).PubMedCrossRefGoogle Scholar
  47. Shin, S., Juan, D. and Rammohan, M. Theophylline pharmacokinetics in normal elderly subjects. Clin. Pharmacol. Ther. 44:522–530 (1988).PubMedCrossRefGoogle Scholar
  48. Skipper, H. E., Schabel, F. M. Jr, Wilcox, W. S. Experimental evaluation of potential anticancer agents. XII. On the criteria and kinetics associated with “curability” of experimental leukemia. Cancer Chemother Rep. 51:125–165 (1967).PubMedGoogle Scholar
  49. Smyth, R. D., Pfeffer, M., Sclazo, A. and Comis, R. L. Bioavailability and pharmacokinetics of etoposide (VP-16). Semin. Oncol. 12(suppl 2):48–51 (1985).PubMedGoogle Scholar
  50. Stewart, C. F., Pieper, J. A., Arbuck, S. G., Evans, W. E. Altered protein binding of etoposide in patients with cancer. Clin, Pharmacol. Ther. 45:49 (1989).CrossRefGoogle Scholar
  51. Tannock, I. F., Boyd, N. F., DeBoer, G., Erlichman, C., Fine, S. Larocque, G., Mayers, C. Perrault, D. Sutherland, H. A. A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer. J. Clin. Oncol. 6:1377 (1982).Google Scholar
  52. Van Liere, E. J. and Northup, D. W. The emptying time of the stomach of old people. Am. J. Physiol. 134:719 (1941).Google Scholar
  53. Vanzant, F. R., Alvarez, W. C., Eusterman, G. B. The normal range of gastric acidity from youth to old age. Arch. Intern. Med. 49:345 (1932).CrossRefGoogle Scholar
  54. Vestal, R. E., Norris, A. H., Tobin, Cohen, B. H., Shock, N. W., Andres, R. Antipyrine metabolism in man: influence of age, alcohol, caffeine, and smoking. Clin. Pharmacol. Ther. 18:425 (1975).PubMedGoogle Scholar
  55. Williams, T. F. Aging or disease. Clin. Pharmacol Ther. 42:663 (1987).PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1993

Authors and Affiliations

  • Ronald A. Fleming
    • 1
  • Robert L. Capizzi
    • 1
  1. 1.Department of Medicine Section on Hematology/OncologyComprehensive Cancer Center Wake Forest University Bowman Gray School of MedicineUSA

Personalised recommendations